HERTHENA-Lung01 pivotal data demonstrate potential of patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer
TROPION-Lung04 late-breaking results continue to show promise of datopotamabderuxtecan-based combinations in patients with non-small cell lung cancer without actionable genomic alterations
Investor meeting to discuss WCLC presentations
BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC23) being held September 9-12, 2023.
Data at WCLC showcasing the company’s progress in creating new standards of care for patients with lung cancer will include primary results of the HERTHENA-Lung01 pivotal phase 2 trial evaluating patritumab deruxtecan (HER3-DXd) in patients with EGFR-mutated NSCLC and late-breaking interim results of the TROPION-Lung04 phase 1b trial evaluating datopotamab deruxtecan (Dato-DXd) in combination with durvalumab with or without carboplatin in patients with metastatic NSCLC without actionable genomic alterations. Data from both trials will be presented for the first time as oral presentations.
Updates from other ongoing trials including the primary analysis of the DESTINY-Lung02 phase 2 trial evaluating ENHERTU in HER2mutant metastatic NSCLC and updated data from a phase 1/2 trial evaluating ifinatamab deruxtecan (I-DXd) in refractory SCLC also will be highlighted as oral presentations.
“Data at WCLC from four of our DXd antibody drug conjugates in populations across several different subtypes of non-small cell lung cancer and small cell lung cancer continue to demonstrate Daiichi Sankyo’s commitment to creating new standards of care for these patients,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “We look forward to presenting for the first time important data from our pivotal HERTHENA-Lung01 trial of patritumabderuxtecan in patients with EGFR-mutated metastatic non-small cell lung cancer and TROPION-Lung04 evaluating datopotamabderuxtecan in combination with durvalumab with or without chemotherapy in patients with metastatic non-small cell lung cancer.”
Trials-in-progress poster presentations of the TROPION-Lung08 and AVANZAR phase 3 trials evaluating datopotamabderuxtecan-based combinations in patients with first line metastatic NSCLC and a phase 2 trial evaluating ifinatamabderuxtecan in patients with previously treated extensive-stage SCLC also will be presented.
Daiichi Sankyo will hold a virtual conference call for investors on Monday, September 11, 2023 from 7:00 to 8:30 pm EDT / Tuesday, September 12, 2023 from 8:00 to 9:30 am JST. Executives from Daiichi Sankyo will provide an overview of the WCLC research data and address questions.
Highlights of data from Daiichi Sankyo’s DXd ADC portfolio at 2023 WCLC include:
Presentation Title
Lead Author
Session
Presentation Time
Patritumab Deruxtecan (HER3-DXd)
Patritumab deruxtecan (HER3-DXd) in EGFR-mutated
NSCLC following EGFR TKI and platinum-based
chemotherapy: HERTHENA-Lung01
H.A. Yu
OA05.03
Oral Presentation
Sunday, September 10
3:02 - 3:12 pm SGT
Clinical outcomes of real-world treatment for metastatic
EGFRm NSCLC after osimertinib and platinum-based
chemotherapy
J. Patel
P2.31-10
Poster Presentation
Monday, September 11
6:00 - 7:30 pm SGT
DatopotamabDeruxtecan (Dato-DXd)
Datopotamabderuxtecan (Dato-DXd) + durvalumab ±
carboplatin in advanced/metastatic NSCLC: initial results
from phase 1b TROPION-Lung04
K.P. Papadopoulous
OA05.06
LBA Oral Presentation
Sunday, September 10
3:32 - 3:42 pm SGT
TROPION-Lung08: datopotamabderuxtecan plus
pembrolizumab in untreated advanced/metastatic non-small
cell lung cancer (NSCLC)
C. Zhou
P2.08-01
Poster Presentation
Monday, September 11
6:00 - 7:30 pm SGT
AVANZAR: Phase III Study of datopotamab deruxtecan
(Dato-DXd) + durvalumab + carboplatin as 1L treatment of
advanced/metastatic NSCLC
C. Aggarwal
P2.04-02
Poster Presentation
Monday, September 11
6:00 - 7:30 pm SGT
ENHERTU (trastuzumab deruxtecan; T-DXd)
Trastuzumab deruxtecan in patients with HER2mutant
metastatic non-small cell lung cancer: primary results of
DESTINY-Lung02
P. Jänne
MA13.10
Mini Oral Presentation
Monday, September 11
4:25 - 4:30 pm SGT
IfinatamabDeruxtecan (I-DXd)
Ifinatamabderuxtecan (I-DXd; DS-7300) in patients with
refractory SCLC: a subgroup analysis of a phase 1/2 study
M. Johnson
OA05.05
Oral Presentation
Sunday, September 10
3:22 - 3:32 pm SGT
A phase 2 study of ifinatamabderuxtecan (I-DXd; DS-7300)
in patients with previously treated ES-SCLC
C. Rudin
P2.16-06
Poster Presentation
Monday, September 11
6:00 - 7:30 pm SGT
About the DXd ADC Portfolio of Daiichi Sankyo
The DXd ADC portfolio of Daiichi Sankyo currently consists of five ADCs in clinical development across multiple types of cancer. The company’s clinical trial stage DXd ADCs include ENHERTU, a HER2 directed ADC, and datopotamabderuxtecan (Dato-DXd), a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca; and patritumabderuxtecan (HER3-DXd), a HER3 directed ADC. Two additional ADCs including ifinatamab deruxtecan (I-DXd; DS-7300), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd; DS-6000), a CDH6 directed ADC, are being developed through a strategic early-stage research collaboration with Sarah Cannon Research Institute.
Designed using Daiichi Sankyo’s proprietary DXd ADC technology, each ADC targets and delivers a cytotoxic payload inside cancer cells that express a specific cell surface antigen. Each ADC consists of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.
Datopotamabderuxtecan, ifinatamabderuxtecan, patritumabderuxtecan and raludotatug deruxtecan are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established.
About Daiichi SankyoDaiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit .
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.